Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge - Wikidata - thesis-toulmin - TriplyDB

Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge

Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge

http://www.wikidata.org/entity/Q33284583

about

A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease Anthrax prophylaxis: recent advances and future directions Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents Anthrax vaccination strategies Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge Preparation of alginate coated chitosan microparticles for vaccine delivery Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi.Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity.Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies Nanomedicine in the Management of Microbial Infection - Overview and Perspectives Colonic immune stimulation by targeted oral vaccine.A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge.Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines Nanoemulsion-based mucosal adjuvant induces apoptosis in human epithelial cells.Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants.Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure.Modified Nanoemulsions with Iron Oxide for Magnetic Resonance Imaging Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.Nanoemulsion nasal adjuvant W₈₀5EC induces dendritic cell engulfment of antigen-primed epithelial cells.In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant.Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking.Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant.Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant.Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.Progress towards a needle-free hepatitis B vaccine.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances.Applications of nanotechnology for immunology.Anthrax vaccines: present status and future prospects.Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives.Nasal-nanotechnology: revolution for efficient therapeutics delivery.Oral delivery of nanoparticle-based vaccines.Human serum contains a protease that protects against cytotoxic activity of Bacillus anthracis lethal toxin in vitro.

P2860

Q21560951-E73C3580-123F-4AC8-8DEA-81857768C3B8 Q26781366-D6BCB093-91D0-4D7A-96D8-B9A6F63E13BF Q27011190-313F9E8A-120D-42E0-8A21-A26F2C98254D Q28384852-9ED51639-0D0A-425F-9013-9023349423D0 Q28392248-BABCE175-C611-4A45-A8DF-5E22A5A961F3 Q30421413-CB83EE3D-A77C-4541-9645-8BACB34F6B77 Q33359620-594F2ED8-719F-4F48-B812-E6D5A6CD0924 Q33360151-BF5A8711-A3A9-4388-9400-8A3FF611F0D0 Q33385532-5828F478-AC9F-4F77-9529-D6729E8F3B81 Q33396429-24EB878A-8EBA-4584-9EB8-14F9DC5A22BC Q33601917-CDDB93E4-1BC4-4C98-9F14-05D01E21E25D Q33650861-AC425C56-6A5F-4F98-8145-88928F0E9303 Q34121874-1B0E778E-9F35-4F64-AB18-639802AADBFE Q34245494-94897F12-9FA5-4F47-9B13-7DBAAC341F8D Q34576128-6644DA57-BAD6-464B-AAEF-33846265D143 Q34700706-12514F4B-9C2E-4A79-B281-54894461B353 Q35049480-CC5C2050-8351-4D63-9C1C-02A72F67CA9A Q35434746-20E485CB-2031-42FE-BB35-74B307B2BD2D Q35593603-E6981C9C-3689-4A48-8A2F-7A0BC296EFC8 Q36122915-0635CDD2-9688-4255-B2FE-7B86694E2880 Q36320689-ED1B53A2-590B-415A-9F25-A1D81E1D9A45 Q36523135-ED781F61-8652-41F7-8EBE-D284E205C085 Q36565552-93D82D67-8068-4389-9F03-076573128E4A Q37032826-F2C39BF4-00AB-4C9D-AB99-6B1503F070D5 Q37130834-DC12577B-08C8-4A76-86CE-A3236756D8FB Q37320191-6077C518-2495-4F1D-ACD1-D93EE6105F59 Q37404847-0D7A7345-9D13-4E2D-B756-7C2D9922545B Q37594498-5E4C22D4-DDEF-4134-9F46-ACC079C0579A Q37627725-9DEA5F3B-9B95-41CE-B2DF-AF0FAC5A7E98 Q37724921-AE134F40-B1A8-44B3-B1CE-D45273168099 Q37792984-D90DDC44-27FC-48F3-9B7D-F83C93959C24 Q37810816-2B60960C-57DF-49D9-9041-2DADA468CCE9 Q37812128-39E85B2C-A856-4CD8-B183-B1464C7E4668 Q37818332-8C83B95E-83FD-41B6-B3C8-AE00B72A5163 Q38123937-D3364B8D-56EF-4CC6-A3D4-6163EC88676A Q38132268-6D341459-272D-4C2C-B503-548FB3D91B75 Q38215454-140E0FF7-E453-49E9-BF56-19F303FF0408 Q38217878-7C7DAB02-343F-45C9-A717-56B295D92BF5 Q38243119-D3870AB7-7954-4250-ACB3-6F0A1A761C47 Q39755368-1889FCCE-D546-4CA5-8748-B766023CD07B

P2860

Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge

http://www.wikidata.org/entity/Q33284583

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Mucosal immunization with a no ...... llus anthracis spore challenge

@ast

Mucosal immunization with a no ...... llus anthracis spore challenge

@en

type

label

Mucosal immunization with a no ...... llus anthracis spore challenge

@ast

Mucosal immunization with a no ...... llus anthracis spore challenge

@en

prefLabel

Mucosal immunization with a no ...... llus anthracis spore challenge

@ast

Mucosal immunization with a no ...... llus anthracis spore challenge

@en

P1433

Q33284583-A4815FA2-DC2A-4B49-ACBB-697C21515A66

P1476

Q33284583-473AC0C7-54AD-4BBB-9BD4-99FA76A6C5DE

P2093

Q33284583-3E0E08FE-3CD0-4583-A378-02486EBA16A5

Q33284583-91CADFDF-A96F-4BAE-ADB6-D306566D6608

Q33284583-94081D65-7B2E-466A-B35F-BC1B755AAC8C

Q33284583-9D12A972-602C-4E5E-8565-797AF1176421

Q33284583-9F19843B-1FA8-4123-B36F-6C4D3C7E4360

Q33284583-A4C1452F-BD45-4B09-978E-BD3EE55572D3

Q33284583-FBF3C9E9-1A05-4D42-99DF-34925C52267B

P2860

Q33284583-028D291D-131D-4535-8424-8E48AE0249F8

Q33284583-04AB191E-CFB8-44CA-A2A6-33C7EFF7B9E3

Q33284583-10B2DB5F-D64A-494D-B453-082BC5386FB8

Q33284583-1D6A1D58-029C-4308-B7D2-A4314D10DED1

Q33284583-1E250CEB-9016-4F58-BDB7-987294037C2A

Q33284583-23304B4E-F79F-4FBD-9BC7-15C7A6E3E82C

Q33284583-26703ACF-69DD-4769-B524-13EC8119FFE7

Q33284583-2C56F6B1-FA94-4B3C-A5BC-BAA982C7DF98

Q33284583-2DBAED68-6FDA-422D-9E4A-2E2DEFA742D4

Q33284583-2EF81AEA-6775-475D-87E9-EBC11F1E086F

P304

Q33284583-22578F9F-5B66-4EF9-8138-B70089A2F749

P31

Q33284583-713A1BAF-98BC-4B37-BE8B-71761A2BFA26

P356

Q33284583-17390E53-4BB3-4BF4-9E22-DCD744FAA360

P407

Q33284583-A2C8DE53-F62A-4D53-99F5-12D1451F67BF

P433

Q33284583-7AB6A300-3F63-4A9F-B671-BBEB52A99B94

P478

Q33284583-7EF7A169-A4D0-4EA1-B2D8-92B4B6342810

P577

Q33284583-8CD903D7-B923-48AE-A503-BEFFBDE62A67

P698

Q33284583-9C9AC1C7-A396-48B6-9862-56E9CFF90E3F

P921

Q33284583-97E906B9-B7FB-4693-9047-412F056F1D07

P932

Q33284583-99E80141-B3B0-4E01-ABCA-5B09EE970C61

P356

P1433

Infection and Immunity

P1476

Mucosal immunization with a no ...... llus anthracis spore challenge

@en

P2093

Anna U Bielinska

http://www.w3.org/2001/XMLSchema#string

James R Baker

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Landers

http://www.w3.org/2001/XMLSchema#string

Johnny W Peterson

http://www.w3.org/2001/XMLSchema#string

Katarzyna W Janczak

http://www.w3.org/2001/XMLSchema#string

Laurie E Sower

http://www.w3.org/2001/XMLSchema#string

Paul Makidon

http://www.w3.org/2001/XMLSchema#string

P2860

Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax

Field Evaluation of a Human Anthrax Vaccine

Taking the sting out of the anthrax vaccine

Anthrax vaccines: past, present and future

Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.

Development of an in vitro-based potency assay for anthrax vaccine.

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen.

Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine.

P304

4020-4029

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.00070-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17502384

http://www.w3.org/2001/XMLSchema#string

P921

P932

1952013

http://www.w3.org/2001/XMLSchema#string